Abstracts Archive - Page 995 of 2607 - ACR Meeting Abstracts

Abstract Number: 823 • 2019 ACR/ARP Annual Meeting
The Risk of Venous Thromboembolism in Patients with Psoriatic Disease and Rheumatoid Arthritis, a Population-based Study
Lingyi Li¹, Na Lu ¹, Eric Sayre ¹, Hui Xie ², Diane Lacaille ³, John Esdaile ⁴ and J. Antonio Avina-Zubieta ⁵, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada, ³Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁵Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Venous thromboembolism (VTE, which includes pulmonary embolism [PE] and deep vein thrombosis [DVT]) is associated with increased morbidity and mortality. Previous studies have shown…
Abstract Number: 824 • 2019 ACR/ARP Annual Meeting
Results from a Randomized Controlled Trial of the Safety of the Live Varicella Vaccine in TNF-Treated Patients
Jeffrey Curtis¹, S Louis Bridges ², Stacey S Cofield ², John Bassler ¹, Theresa Ford ³, Stephen Lindsey ⁴, Alan Kivitz ⁵, Ilhem Messaoudi ⁶, Kaleb Michaud ⁷, Joseph Huffstutter ⁸, Ted Mikuls ⁹, David Ridley ¹⁰, William Shergy ¹¹, Sarah Siegel ¹² and Kevin Winthrop ¹³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³North Georgia Rheumatology Group, PC, Lawrenceville, GA, ⁴Ochsner Clinic Foundation, Baton Rouge, LA, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶University of California Irvine, Irvine, CA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Arthritis Associates, Hixon, TN, ⁹VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ¹⁰St. Paul Rheumatology, Eagan, MN, ¹¹Rheumatology Associates of North Alabama, Huntsville, AL, ¹²Oregon Health Science University, Portland, OR, ¹³Oregon Health and Science University, Portland, OR
Background/Purpose: There has been minimal evaluation of the safety of live virus vaccines in patients receiving biologic therapies who may be immunocompromised. The Varicella Zoster…
Abstract Number: 825 • 2019 ACR/ARP Annual Meeting
Systemic Sclerosis Deaths at Younger Ages Have Decreased over the past Five Decades
Eric Yen¹, Devanshu Singh ² and Ram Raj Singh ¹, ¹UCLA, Los Angeles, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: Patients with systemic sclerosis (SSc) can die prematurely of disease-associated complications. Over the past 2 decades, several advances in the treatment of SSc-associated complications…
Abstract Number: 826 • 2019 ACR/ARP Annual Meeting
Immune-Mediated Inflammatory Diseases (IMID) Collectively Rank Among the Leading Causes of Death
Meifang Wu¹, Eric Yen ² and Ram Raj Singh ², ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²UCLA, Los Angeles
Background/Purpose: Almost every organ system can be affected by primary immune-mediated diseases characterized by inflammation and therapeutic response to immune-suppressive or anti-inflammatory drugs. These diseases…
Abstract Number: 827 • 2019 ACR/ARP Annual Meeting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia (FM): Evidence for a Broad Spectrum of Activity on the FM Syndrome
Gregory Sullivan¹, R. Michael Gendreau ², Judith Gendreau ³, Ashild Peters ⁴, Perry Peters ⁵ and Seth Lederman ⁶, ¹Tonix Pharmaceuticals Inc., New York, ²Gendreau Consulting, Poway, CA, ³Tonix Pharmaceuticals Inc, Poway, CA, ⁴Tonix Pharmaceuticals Inc., San Diego, CA, ⁵Tonix Pharmaceuticals Inc, San Diego, CA, ⁶Tonix Pharmaceuticals Inc, New York, NY
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain, unrefreshing sleep, fatigue, and cognitive complaints. TNX-102 SL* is a sublingual (SL) formulation of cyclobenzaprine (CBP)…
Abstract Number: 828 • 2019 ACR/ARP Annual Meeting
A Path Model Analysis of the Cognitive Determinants of Physical Activity Among Patients with Fibromyalgia (FM)
Dennis Ang ¹, Anthony Kaleth ² and William Bush³, ¹Wake Forest School of Medicine, Winston Salem, ²Indiana University-Purdue University Indianapolis, IN, Indianapolis, IN, ³Wake Forest Baptist Medical Center, Winston-Salem, NC
Background/Purpose: In individuals with FM, regular participation in physical activity (PA) is associated with improvement of symptoms, daily physical functioning, and overall well-being. Given the…
Abstract Number: 829 • 2019 ACR/ARP Annual Meeting
Dietary Intake Does Not Explain Microbiome Alterations or Symptom Severity in Fibromyalgia
Amir minerbi¹, Stéphanie Chevalier ², Abraham Anjarkouchian ², Audrey Moyen ², Yoram Shir ¹ and Mary-Ann Fitzcharles ¹, ¹Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, Canada, ²School of Human Nutrition, McGill University, Montreal, Canada
Background/Purpose: We have recently reported significant alterations in gut microbiome compositionin women with fibromyalgia (FM). As gut microbiome is affected by diet, differences in nutritional…
Abstract Number: 830 • 2019 ACR/ARP Annual Meeting
The Efficacy of Non-Pharmacological Interventions for Fibromyalgia: A Systematic Review with Meta-Analysis
Burak Kundakci¹, Jaspreet Kaur ², Siew-Li Goh ³, Michelle Hall ⁴, Michael Doherty ⁵, Weiya Zhang ⁵ and Abhishek Abhishek ⁶, ¹Academic Rheumatology, Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Nottingham, UK/Arthritis Research UK Pain Centre, Nottingham, UK, Nottingham, United Kingdom, ²Academic Rheumatology, Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Nottingham, UK, Nottingham, United Kingdom, ³Sports Medicine Unit, University of Malaya, Kuala Lumpur, Malaysia, Kuala Lumpur, Malaysia, ⁴Academic Rheumatology, Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Nottingham, UK/Arthritis Research UK Pain Centre, Nottingham, UK/National Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham, UK/Division of Physiotherapy and Rehabilitation Sciences, University of Nottingham, Nottingham, UK, Nottingham, United Kingdom, ⁵Academic Rheumatology, Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Nottingham, UK/Arthritis Research UK Pain Centre, Nottingham, UK/National Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham, UK, Nottingham, United Kingdom, ⁶Academic Rheumatology, Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Nottingham, UK/National Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham, UK, Nottingham, United Kingdom
Background/Purpose: Non-pharmacological interventions are recommended as first-line treatment for fibromyalgia (FM)1. However, the evidence base supporting this has not been updated comprehensively, and the recent…
Abstract Number: 831 • 2019 ACR/ARP Annual Meeting
Maintaining Musculoskeletal Health: A Randomized Controlled Prevention Trial Amongst People at High Risk of Developing Chronic Widespread Pain
Gary Macfarlane¹, Marcus Beasley ¹, Neil Scott ¹, Gordon Prescott ², Paul McNamee ¹, John McBeth ³, Gareth Jones ¹, Neil Basu ⁴, Phil Hannaford ¹, Phil Keeley ⁵ and Karina Lovell ⁶, ¹University of Aberdeen, Aberdeen, United Kingdom, ²University of Central Lancashire, Preston, United Kingdom, ³Versus Arthritis Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, Manchester, United Kingdom, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵University of Huddersfield, Huddersfield, United Kingdom, ⁶University of Manchester, Manchester, United Kingdom
Background/Purpose: Cognitive behaviour therapy (CBT) is effective in the management of fibromyalgia (and its characteristic feature Chronic Widespread Pain (CWP). CBT is recommended in all…
Abstract Number: 832 • 2019 ACR/ARP Annual Meeting
Diagnosis of Fibromyalgia: Comparison of AAPT and ACR Criteria
Marco Antivalle¹, Federica Rigamonti ¹, Michele Agosti ¹ and Piercarlo Sarzi-Puttini ¹, ¹L. Sacco University Hospital, Milano, Italy
Background/Purpose: In recent years, the diagnostic criteria for fibromyalgia (FM) have been reviewed multiple times, up to the publication of the provisional criteria of the…
Abstract Number: 833 • 2019 ACR/ARP Annual Meeting
Effect of a Mobile App to Monitor Patient Reported Outcomes in Rheumatoid Arthritis: A Randomized Controlled Trial
Yvonne Lee¹, Fengxin Lu ², Joshua Colls ², Meredith Murray ², Dong Suh ², Jing Song ³, Julia (Jungwha) Lee ⁴, Dorothy Dunlop ⁴ and Daniel Solomon ⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, ²Brigham and Women's Hospital, Boston, MA, ³Northwestern University Feinberg School of Medicine, Worthington, OH, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA
Background/Purpose: Treat to target (TTT) is an effective strategy to improve outcomes in rheumatoid arthritis (RA). However, barriers to TTT include frequent clinic visits, poor…
Abstract Number: 834 • 2019 ACR/ARP Annual Meeting
Implementing Patient-Reported Outcome Measures in Clinical Care: Rheumatologist Perspectives on Opportunities and Challenges
Shanthini Kasturi¹, John Wong ¹, Lisa Mandl ², Timothy McAlindon ³ and Amy LeClair ¹, ¹Tufts Medical Center, Boston, ²Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY, ³Tufts Medical Center, Boston, MA
Background/Purpose: There is growing interest in the implementation of patient-reported outcome measures (PROMs) in clinical rheumatology to promote patient-centered care and to meet the mandates…
Abstract Number: 835 • 2019 ACR/ARP Annual Meeting
High Baseline Patient’s Compared with Evaluator’s Global Assessment Is Associated with Lower Retention and Remission Rates of First TNF Inhibitor in Psoriatic Arthritis Patients – Data from the EuroSpA Research Collaboration Network
Brigitte Michelsen¹, Lykke Midtbøll Ørnbjerg ², Herman Mann ³, Tore Kvien ⁴, Michael J. Nissen ⁵, Maria José Santos ⁶, Dan Nordström ⁷, Lennart Jacobsson ⁸, Ziga Rotar ⁹, Bjorn Gudbjornsson ¹⁰, Süleyman Serdar Koca ¹¹, Catalin Codreanu ¹², Manuel Pombo-Suarez ¹³, Irene van der Horst-Bruinsma ¹⁴, Anne Gitte Loft ¹⁵, Karel Pavelka ³, Eirik Kristianslund ¹⁶, Burkhard Moeller ¹⁷, Elsa Vieira-Sousa ¹⁸, Anna Mari Hokkanen ¹⁹, Ulf Lindström ²⁰, Matija Tomsic ²¹, Thorvardur J Love ²², Abdurrahman Tufan ²³, Ruxandra IONESCU ²⁴, Carlos Sánchez-Piedra ²⁵, Marleen van de Sande ²⁶, Gary Macfarlane ²⁷, Florenzo Iannone ²⁸, Lise Hyldstrup ², Mikkel Østergaard ²⁹ and Merete Lund Hetland ³⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁴Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁵University Hospital Geneva, Geneva, Switzerland, ⁶Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ⁷Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ⁸Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, ⁹UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹⁰Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹¹Fırat University School of Medicine Division of Rheumatology, Elazığ, Turkey, ¹²Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹³Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ¹⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ¹⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ¹⁶Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ¹⁷University Hospital Bern, Bern, Switzerland, ¹⁸Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, ¹⁹Helsinki University Hospital, Helsinki, Finland, ²⁰University of Gothenburg, Gothenburg, Sweden, ²¹Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ²²Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ²³Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey, Ankara, Turkey, ²⁴SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁵Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²⁶Amsterdam UMC, Amsterdam, Netherlands, ²⁷University of Aberdeen, Aberdeen, United Kingdom, ²⁸Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ²⁹Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ³⁰DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Discordance between baseline patient’s and evaluator’s global assessment of disease activity is common1 and may reduce the likelihood of remission following tumor necrosis factor…
Abstract Number: 836 • 2019 ACR/ARP Annual Meeting
Patient-Reported Outcomes from a Randomised, Open-Label, Parallel-Group Study Evaluating Ixekizumab versus Adalimumab in Patients with PsA Who Are Biologic DMARD Naïve: 24-Week Results
Filip Van den Bosch¹, Lars-Erik Kristensen ², Dennis McGonagle ³, Maurizio Rossini ⁴, Soyi Liu-Leage ⁵, Christophe Sapin ⁵, Gabriella Meszaros ⁵ and Joseph Merola ⁶, ¹Ghent University Hospital, Ghent, Belgium, ²Copenhagen University Hospital, Bispebjerg-Frederiksberg, Denmark, ³University of Leeds, Leeds, United Kingdom, ⁴University of Verona, Verona, Italy, ⁵Eli Lilly and Company, Indianapolis, ⁶Harvard Medical School, Brigham and Women’s Hospital, Boston, MA
Background/Purpose: Therapeutic options for patients with PsA are increasing but data directly comparing biologics are limited. The multicentre, open-label SPIRIT-H2H trial (NCT03151551) evaluated the efficacy…
Abstract Number: 837 • 2019 ACR/ARP Annual Meeting
Does Discordance Between Baseline Patient’s and Evaluator’s Global Assessment of Disease Activity Impact Retention and Remission Rates of a First TNF Inhibitor in Patients with Axial Spondyloarthritis? Data from the EuroSpA Research Collaboration Network
Brigitte Michelsen¹, Lykke Midtbøll Ørnbjerg ², Anne Gitte Loft ³, Tore Kvien ⁴, Adrian Ciurea ⁵, Herman Mann ⁶, Kari K. Eklund ⁷, Ayten Yazici ⁸, Maria José Santos ⁹, Johan Askling ¹⁰, Ziga Rotar ¹¹, Bjorn Gudbjornsson ¹², Manuel Pombo-Suarez ¹³, Catalin Codreanu ¹⁴, Irene van der Horst-Bruinsma ¹⁵, Eirik Kristianslund ¹⁶, Michael J. Nissen ¹⁷, Karel Pavelka ⁶, Nina Trokovic ¹⁸, Nevsun Inanc ¹⁹, Elsa Vieira-Sousa ²⁰, Daniela DiGuiseppe ²¹, Matija Tomsic ²², Arni Jon Geirsson ²³, Ruxandra IONESCU ²⁴, Marleen van de Sande ²⁵, Florenzo Iannone ²⁶, Carlos Sánchez-Piedra ²⁷, Gareth Jones ²⁸, Lise Hyldstrup ², Merete Lund Hetland ²⁹ and Mikkel Østergaard ³⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ⁴Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁵University Hospital Zürich, Zürich, Switzerland, ⁶Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁷ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, ⁸Kocaeli University, Faculty of Medicine, Division of Rheumatology, Kocaeli, Kocaeli, Turkey, ⁹Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰Karolinska Institutet, Stockholm, Sweden, ¹¹UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹²Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹³Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ¹⁴Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹⁵Amsterdam University Medical Center, Amsterdam, Netherlands, ¹⁶Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ¹⁷University Hospital Geneva, Geneva, Switzerland, ¹⁸Helsinki University Central Hospital, Helsinki, Finland, ¹⁹Marmara University, Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ISTANBUL, Turkey, ²⁰Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, ²¹Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet,, Stockholm, Sweden, ²²Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ²³Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, ²⁴SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁵Amsterdam UMC, Amsterdam, Netherlands, ²⁶Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ²⁷Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²⁸University of Aberdeen, Aberdeen, United Kingdom, ²⁹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ³⁰Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Discordance between baseline patient’s and evaluator’s global assessment of disease activity is common.1 However, the impact of such discordance on retention and remission rates…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].